panitumumab

{
  "id": "MLC-T-ONC-006302",
  "term": "panitumumab",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A drug used alone or with other drugs to treat certain types of colorectal cancer that have spread to other parts of the body. It is used in patients whose cancer has not already been treated or has gotten worse after treatment with other anticancer drugs. It is also being studied in the treatment of other types of cancer. Panitumumab binds to a protein called epidermal growth factor receptor (EGFR), which is found on some normal cells and some types of cancer cells. Blocking this protein may help keep cancer cells from growing. Panitumumab is a type of monoclonal antibody. Also called ABX-EGF and Vectibix.",
    "A human IgG2kappa monoclonal antibody specific for the epidermal growth factor receptor (EGFR). Monoclonal antibody E7.6.3 binds to the EGFR, blocking the binding of epidermal growth factor and transforming growth factor alpha to EGFR-expressing cancer cells and ultimately inhibiting EGFR-dependent cell activation and proliferation."
  ],
  "abbreviation": "MoAb ABX-EGF",
  "synonyms": [
    "ABX-EGF",
    "Vectibix",
    "human IgG2K monoclonal antibody",
    "ABX-EGF, clone E7.6.3",
    "monoclonal antibody ABX-EGF",
    "ABX-EGF monoclonal antibody",
    "monoclonal antibody E7.6.3"
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/panitumumab/"
}